Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of a specific share transaction and does not contain consolidated financial statements.
Material Changes
The filing discloses a specific transaction involving an increase in the notional interest in Ordinary Shares. This change resulted from the re-investment of dividends paid to shareholders on July 14, 2016, under the Company's Deferred Investment Award Programme.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the mechanics of the reported transaction.
Important Facts for Investors
- Transaction Type: Increase in notional interest in Ordinary Shares via dividend re-investment.
- Individual Involved: Ms. E. Walmsley, CEO of GSK Consumer Healthcare.
- Transaction Date: July 14, 2016.
- Instrument Details: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume and Price: 454,329 shares at a price of £16.4900 per share.
- Programme: GSK Deferred Investment Award Programme.